Mallory Morales - Mar 15, 2024 Form 4 Insider Report for Immuneering Corp (IMRX)

Role
Chief Accounting Officer
Signature
/s/ Michael D. Bookman, Attorney-in-Fact for Mallory Morales
Stock symbol
IMRX
Transactions as of
Mar 15, 2024
Transactions value $
$11,046
Form type
4
Date filed
3/25/2024, 09:04 AM
Previous filing
Feb 9, 2024
Next filing
May 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMRX Class A Common Stock Award $7.04K +4.34K +178.47% $1.62 6.78K Mar 15, 2024 Direct F1, F2, F3
transaction IMRX Class A Common Stock Purchase $3.01K +1.11K +16.33% $2.72 7.89K Mar 21, 2024 Direct F4
transaction IMRX Class A Common Stock Purchase $1K +393 +4.98% $2.55 8.28K Mar 22, 2024 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 15, 2023 through March 15, 2024. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.
F2 The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of March 15, 2024.
F3 In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of March 15, 2024.
F4 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.675 to $2.74. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.